Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS

por Nagle, Sarah J, Shah, Nirav N, Ganetsky, Alex, Landsburg, Daniel J, Nasta, Sunita D, Mato, Anthony, Schuster, Stephen J, Reshef, Ran, Tsai, Donald E, Svoboda, Jakub
Publicado 2017

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma

por Nagle, Sarah J, Chong, Elise A, Chekol, Seble, Shah, Nirav N, Nasta, Sunita D, Glatstein, Eli, Plastaras, John P, Torigian, Drew A, Schuster, Stephen J, Svoboda, Jakub
Publicado 2015

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

por Choi, Yun, Caro, Jessica, Li, Xiaochun, Al-Obeidi, Arshed, Kurtz, Sharyn Lynn, Kim, Austin I., Chang, Julie E., Olszewski, Adam J., Zayac, Adam, Matthews, Andrew, Barta, Stefan K., Sundaram, Suchitra, Hernandez-Ilizaliturri, Francisco J., Leslie, Lori A., Caimi, Paolo, Carter, Jordan, David, Kevin A., Evens, Andrew M., Kim, Myung Sun, Nagle, Sarah J., Goldberg, Judith, Diefenbach, Catherine S.
Publicado 2021

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

por Svoboda, Jakub, Bair, Steven M., Landsburg, Daniel J., Nasta, Sunita Dwivedy, Nagle, Sarah J., Barta, Stefan K., Khan, Nadia, Filicko-O'Hara, Joanne, Gaballa, Sameh, Strelec, Lauren, Chong, Elise, Mitnick, Sheryl, Waite, Terease S., King, Cara, Ballard, Hatcher, Youngman, Matthew, Gerson, James, Plastaras, John P., Maity, Amit, Bogusz, Agata M., Hung, Stacy S., Nakamura, Hisae, Nejati, Reza, Steidl, Christian, Lim, Megan, Ruella, Marco, Schuster, Stephen J.
Publicado 2020